ラヴィ・ヴィスウェスワラ
エグゼクティブ・バイスプレジデント
Expertise:
In more than 20 years of consulting and leadership in APAC, Ravi’s expertise has focused on helping clients take big-bet investments in complex and uncertain environments at an asset and portfolio levels. Ravi regularly advises clients on their most critical challenges: decisions to enter new markets, and optimize their portfolios and R&D investments.
また、クライアントの複数年にわたるプログラムを数多く監督してきた経験を持ち、いずれのプログラムにおいても組織に永続的な変革をもたらすと同時に株主価値を大幅に向上させました。
Ravi holds a bachelor’s degree in Technology from Indian Institute of Technology, Chennai, and an MBA from the Indian Institute of Management, Calcutta.
Articles by ラヴィ・ヴィスウェスワラ
Reframing the Challenges of Access and ROI
Pharma companies today are being judged not just on their profitability for shareholders, but also on the extent to which their products are accessible to patients. Today’s Environmental, Social and Governance (ESG) investors want to see evidence of corporate responsibility, for which pharmaceuticals’ surrogate measure is access. While companies such as Novo Nordisk and UCB explicitly include access or related measures as direct performance indicators, eight of the top 20 companies are developing systematic access plans. GSK and Novartis have made specific quantitative commitments to increasing access for their products by 2025. While access has always been of interest as a metric, companies have been discouraged by the trade-off between […]
How Do You Know Your Portfolio Process Is Adding Value?
In 1998, Rob Arnold, Executive Vice President, teamed with some colleagues to publish an article in the Harvard Business Review that highlighted the practical results obtained by applying modern R&D portfolio thinking to SmithKline Beecham’s late-stage assets. SB publicly claimed that the review process had added $2.6 billion in value to the corporation. That team worked with most major pharma companies to apply similar principles in the 1990s, and huge value was unlocked using superior analytic and people process approaches. These approaches were developed to address the most significant challenge of the time: too many assets and not enough investment available. Industry challenges are different today, and more time is […]
Escaping the Chronic Microcap Trap: How Launching Alone Is the Only Option for Growth
As C-suite leaders in pharma wrestle with the pros and cons of launching alone, licensing or partnering with another company to launch their product, one factor they must consider is the impact their decision will have on their current and future market valuation. The question is this: How much of a premium does the market put on a company that chooses to launch and commercialize its product independently? The universe of nanocap and microcap pharma companies continues to grow, creating a backlog of companies trying to chart the course toward becoming a mid-cap or even large-cap company. Clearly, the primary means of reaching that goal is successfully launching and commercializing […]
The Chronic Microcap Trap: How Launch Is The Escape for True Growth
Pre-commercial pharma companies face a common choice: commercialize products independently or collaborate with another pharmaceutical company as a commercialization partner. As the C-suite leaders in these organizations wrestle with the pros and cons of this choice, one factor they must consider is the impact their decision will have on their current and future market valuation. The question is this: How much of a premium does the market put on a company that chooses to launch and commercialize its product independently? This white paper dives deep into the data and discusses how the average market capitalization of a cohort of public companies that developed paths to launch their own products (including […]